NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early...
Fri Feb 15, 2019 07:02
Subject to approval by various courts, the stipulated order from the FTC will block Teva from engaging in reverse-payment patent settlement agreements that would hinder consumer access to The post FTC, Teva reach global settlement to resolve reverse-payment charges appeared first on Pharmaceutical Business review.
Thu Feb 21, 2019 12:31
The financing was led by RA Capital Management and was joined by new investors including Eventide Asset Management, Biotechnology Value Fund, OrbiMed, EcoR1 Capital, Vida Ventures, Curative Ventures The post Peloton Therapeutics secures $150m in Series E financing appeared first on Pharmaceutical Business review.
Thu Feb 21, 2019 10:27
The patent (U.S. Patent Number 10206894) covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts. The new patent broadens the Company’s The post Innovation Pharmaceuticals receives new patent for compounds for use in treatment of oral mucositis appeared first on Pharmaceutical Business review.
Wed Feb 20, 2019 11:50
Entrectinib has been granted priority review for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors in adult and paediatric patients. The The post Roche secures FDA priority review for entrectinib and polatuzumab vedotin appeared first on Pharmaceutical Business review.
Wed Feb 20, 2019 11:50
The recommended dose of Keytruda for the adjuvant treatment of adult patients with melanoma is 200 mg administered as an intravenous infusion over 30 minutes every three weeks The post Merck gets FDA nod for Keytruda as adjuvant treatment for melanoma appeared first on Pharmaceutical Business review.
Wed Feb 20, 2019 11:50
“Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system,” said Andreas Penk, M.D., regional president, The post Pfizer secures approval from European Commission for Avastin biosimilar appeared first on Pharmaceutical Business review.
Wed Feb 20, 2019 11:50
Under the collaboration, the firms will evaluate the safety and tolerability of the combination therapy of Innovent’s Tyvyt (generic name: sintilimab injection), a fully human anti-programmed cell death The post Innovent, Chipscreen Biosciences to assess combination therapy in colorectal cancer patients appeared first on Pharmaceutical Business review.
Tue Feb 19, 2019 13:11
Under the agreement, Knight will initially lend Moksha8 up to US $25 million in working capital funding, of which US $10 million will be issued at closing. Knight The post Knight Therapeutics signs Latin American funding deal with Moksha8 appeared first on Pharmaceutical Business review.
Tue Feb 19, 2019 13:11
Additional work conducted on a drug exposure-response analysis showed a statistically significant response of BNC210 in treatment of PTSD symptoms, as measured by Clinician-Administered PTSD Scale (CAPS-5) at The post Additional data analysis offers greater insight into phase 2 findings of Bionomics’ PTSD drug appeared first on Pharmaceutical Business review.
Tue Feb 19, 2019 11:07
Vitrakvi and BAY 2731954 are oncology compounds, which are being developed for the treatment of advanced solid tumors harboring NTRK gene fusions in adult and pediatric patient population. The post Bayer gets full rights to Vitrakvi, LOXO-195 from Lilly’s Loxo Oncology appeared first on Pharmaceutical Business review.
Tue Feb 19, 2019 11:07
PROVENGE (sipuleucel-T) was the first U.S. Food and Drug Administration (FDA)-approved immunotherapy made from a patient’s own immune cells. “We are pleased to work with Dendreon on this The post Decipher announces research collaboration with Dendreon to identify genomic drivers of patient response to Sipuleucel-T appeared first on Pharmaceutical Business review.
Mon Feb 18, 2019 12:29
The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced The post Bavencio plus Inlyta improves median PFS in renal carcinoma study appeared first on Pharmaceutical Business review.
Mon Feb 18, 2019 12:29
The artificial intelligence software, created by researchers at Imperial College London and the University of Melbourne, has been able to predict the prognosis of patients with ovarian cancer The post Artificial intelligence can predict survival of ovarian cancer patients appeared first on Pharmaceutical Business review.
Mon Feb 18, 2019 12:29
Clinical Trials, Ahead of Print.
Wed Feb 20, 2019 07:11
Clinical Trials, Ahead of Print.
Wed Feb 20, 2019 07:11
Publication date: April 2019Source: Contemporary Clinical Trials, Volume 79Author(s): Benzi M. Kluger, Maya Katz, Nicholas Galifianakis, Steven Z. Pantilat, Jean S. Kutner, Stefan Sillau, Mark Gritz, Jacqueline Jones, Diane Fairclough, Malenna Sumrall, Kirk Hall, Janis MiyasakiAbstractPatients with Parkinson's disease and related disorders (PDRD) and their families have considerable unmet needs including non-motor symptom management, caregiver support, spiritual wellbeing, advance care planning,...
Wed Feb 27, 2019 12:36
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου